Fig. 1 | Scientific Reports

Fig. 1

From: Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II–III non-small cell lung cancer

Fig. 1

Heatmap illustrating the results of Rapid-Neo CGP analysis for all 68 patients. Sequencing was successfully performed in all cases. TMB and MSI status are also presented. TMB is shown as a continuous variable, with darker colors indicating higher values. A cutoff of 10 mutations per megabase (mut/Mb) was used to define TMB-high. MSI is also shown as a continuous variable, with darker colors indicating higher percentages of instability. MSI-high is defined as ≥ 12.5% instability, and MSS as < 12.5%. Driver mutations were identified in 42 patients (61.8%). Notably, even among patients without detectable driver mutations, a substantial number exhibited diverse genetic alterations. CGP, comprehensive genomic profiling; MSI, microsatellite instability; MSS, microsatellite stable; TMB, tumor mutational burden.

Back to article page